HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

QYUNS-B

21.040

+0.6803.34%

Volume:612.62K

Turnover:13.11M

Market Cap:4.78B

PE:-12.57

High:22.120

Open:20.880

Low:20.200

Close:20.360

52wk High:36.500

52wk Low:5.950

Shares:227.07M

HK Float Shares:227.07M

Volume Ratio:0.64

T/O Rate:0.27%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-1.674

ROE:-68.26%

ROA:-10.67%

PB:19.28

PE(LYR):-12.57

PS:13.62

Loading ...

Overview Company News Filings

Qyuns Therapeutics (Stock Code: 2509) and Roche Ink Global Exclusive License for QX031N

Bulletin Express

Qyuns Therapeutics (2509) Announces Positive Phase III Results for Crusekitug in Ankylosing Spondylitis

Bulletin Express

QYUNS-B (02509) Enters Global Exclusive Licensing Agreement with Roche for QX031N

QYUNS-B (02509): QX002N (Lusekizumab) Phase III Clinical Trial Results for Ankylosing Spondylitis Presented at 2025 ACR Annual Meeting

Qyuns Therapeutics Grants Roche Global Exclusive License for QX031N

Qyuns Therapeutics Reports Positive Phase III Results for Crusekitug in Ankylosing Spondylitis

Qyuns Therapeutics - Grants Roche Global Exclusive Right to Develop, Others QX031n

THOMSON REUTERS

Qyuns Therapeutics - to Receive $75 Mln Upfront and up to $995 Mln in Milestones

THOMSON REUTERS

Qyuns Therapeutics - Announces Exclusive License Agreement With F. Hoffmann-La Roche

THOMSON REUTERS

HK Movers | Biomedical Stocks Surge With TransThera Sciences up 42%

Tiger Newspress

Qyuns Therapeutics Unit Passes EU Qualified Person Audit; Shares Down 8%

MT Newswires Live

QYUNS-B (02509): Subsidiary Successfully Passes EU Qualified Person Audit for Manufacturing Base

Qyuns Therapeutics Industrialization Base Passes EU QP Audit Meeting EU GMP Standards

Qyuns Therapeutics (SEHK:2509): Evaluating Valuation After Recent Stock Surge

Simply Wall St.

Tianfeng Securities Initiates Coverage on QYUNS-B (02509) with "Buy" Rating, Target Price HK$40.25

Hong Kong Pharmaceuticals Rise as Trump Drug Tariffs Show Limited Impact; Q4 BD Events Expected

Hong Kong Stock Alert | QYUNS-B (02509) Surges Over 10% Again as Mature Pipeline Enters Monetization Phase, Seleixin Market Sales Accelerating

Hong Kong Stock Alert | QYUNS-B (02509) Surges Over 7% Intraday as Company Accelerates Pipeline Market Potential Realization with Bispecific Antibody Programs Targeting International Markets

Qyuns Therapeutics Raises HK$100 Million via Share Placement; Shares Rise 3%

MT Newswires Live

QYUNS-B (02509) Completes Placement of 5 Million Shares

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/02509/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02509","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02509\",,,,,undefined,":{"symbol":"02509","market":"HK","secType":"STK","nameCN":"QYUNS-B","latestPrice":21.04,"timestamp":1763107691009,"preClose":20.36,"halted":0,"volume":612617,"delay":0,"floatShares":227071600,"shares":227071600,"eps":-1.6742798158541135,"marketStatus":"Closed","change":0.68,"latestTime":"11-14 16:08:11","open":20.88,"high":22.12,"low":20.2,"amount":13113144,"amplitude":0.094303,"askPrice":21.08,"askSize":800,"bidPrice":21.04,"bidSize":4200,"shortable":3,"etf":0,"ttmEps":-0.9454931782849325,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1763343000000},"marketStatusCode":5,"adr":0,"listingDate":1710864000000,"exchange":"SEHK","adjPreClose":20.36,"openAndCloseTimeList":[[1763083800000,1763092800000],[1763096400000,1763107200000]],"volumeRatio":0.641342,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02509\",,,,,undefined,":{"symbol":"02509","floatShares":227071600,"roa":"-10.67%","roe":"-68.26%","lyrEps":-1.674161,"volumeRatio":0.641342,"shares":227071600,"dividePrice":0,"high":22.12,"amplitude":0.094303,"preClose":20.36,"low":20.2,"week52Low":5.95,"pbRate":"19.28","psRate":"13.62","week52High":36.5,"institutionHeld":0,"latestPrice":21.04,"committee":0.68,"eps":-1.6741609461476274,"divideRate":0,"volume":612617,"delay":0,"ttmEps":-0.9454260506187425,"open":20.88,"prevYearClose":7.38,"prevWeekClose":19.25,"prevMonthClose":21.78,"prevQuarterClose":34.88,"fiveDayClose":19.25,"twentyDayClose":28.5,"sixtyDayClose":24.94},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02509\",params:#limit:5,,,undefined,":[{"date":"2025-03-28","symbol":"02509","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1743125400000,"name":null,"time":"Post Market","dateTimestamp":1743091200000,"actualEps":null},{"date":"2024-08-15","symbol":"02509","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1723685400000,"name":null,"time":"","dateTimestamp":1723651200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02509\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02509\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02509\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02509","date":"2025-11-13","current":-22.256841,"percent":0.137931,"low":-38.274716,"twenty":-12.407907,"median":-9.107782,"eighty":-5.151718,"high":-3.10587,"avg":-11.138615,"sd":8.258911,"marketCap":4610921056},"quantilePoints":[{"date":"2024-03-22","current":-9.005941,"twenty":-9.920087,"median":-9.005941,"eighty":-8.797979,"marketCap":4652400020},{"date":"2024-03-28","current":-9.367246,"twenty":-9.484937,"median":-9.005941,"eighty":-8.416995,"marketCap":4821843660},{"date":"2024-04-05","current":-8.872714,"twenty":-9.396669,"median":-8.977885,"eighty":-8.598751,"marketCap":4565907160},{"date":"2024-04-12","current":-9.165919,"twenty":-9.386227,"median":-9.126184,"eighty":-8.830039,"marketCap":4719469060},{"date":"2024-04-19","current":-9.074252,"twenty":-9.304842,"median":-9.125412,"eighty":-8.934406,"marketCap":4668281760},{"date":"2024-04-26","current":-9.882424,"twenty":-9.513374,"median":-9.232059,"eighty":-8.994719,"marketCap":5077780160},{"date":"2024-05-03","current":-10.208268,"twenty":-9.517937,"median":-9.234052,"eighty":-9.046928,"marketCap":5241579520},{"date":"2024-05-10","current":-10.950727,"twenty":-10.058378,"median":-9.328243,"eighty":-9.081967,"marketCap":6018140360},{"date":"2024-05-17","current":-11.513141,"twenty":-10.522167,"median":-9.424295,"eighty":-9.09098,"marketCap":6317937020},{"date":"2024-05-24","current":-11.397533,"twenty":-11.287555,"median":-9.513128,"eighty":-9.098359,"marketCap":6240211960},{"date":"2024-05-31","current":-10.960491,"twenty":-11.380385,"median":-9.702863,"eighty":-9.110289,"marketCap":6007036780},{"date":"2024-06-07","current":-9.736726,"twenty":-11.329803,"median":-9.882424,"eighty":-9.125257,"marketCap":5329718400},{"date":"2024-06-14","current":-9.786262,"twenty":-11.239813,"median":-9.736726,"eighty":-9.134131,"marketCap":5351925560},{"date":"2024-06-21","current":-11.51586,"twenty":-11.394726,"median":-9.834343,"eighty":-9.179147,"marketCap":6284626280},{"date":"2024-06-28","current":-7.449742,"twenty":-11.394726,"median":-9.882424,"eighty":-9.134131,"marketCap":4063910280},{"date":"2024-07-05","current":-8.013266,"twenty":-11.3835,"median":-9.736726,"eighty":-9.096784,"marketCap":4370369088},{"date":"2024-07-12","current":-8.782148,"twenty":-11.375713,"median":-9.612459,"eighty":-8.973485,"marketCap":4796746560},{"date":"2024-07-19","current":-8.033889,"twenty":-11.260937,"median":-9.536435,"eighty":-8.759388,"marketCap":4388134816},{"date":"2024-07-26","current":-8.627957,"twenty":-11.24224,"median":-9.513744,"eighty":-8.627957,"marketCap":4730125080},{"date":"2024-08-02","current":-9.119354,"twenty":-11.155317,"median":-9.51436,"eighty":-8.659337,"marketCap":4996611000},{"date":"2024-08-09","current":-9.602516,"twenty":-11.096166,"median":-9.502501,"eighty":-8.759388,"marketCap":5296407660},{"date":"2024-08-16","current":-9.659156,"twenty":-11.082764,"median":-9.523303,"eighty":-8.782148,"marketCap":5329718400},{"date":"2024-08-23","current":-11.457751,"twenty":-11.24224,"median":-9.560506,"eighty":-8.785621,"marketCap":5274200500},{"date":"2024-08-30","current":-11.261539,"twenty":-11.260937,"median":-9.602516,"eighty":-8.853804,"marketCap":5218682600},{"date":"2024-09-06","current":-12.381731,"twenty":-11.301814,"median":-9.616314,"eighty":-8.872714,"marketCap":5740550860},{"date":"2024-09-13","current":-12.966504,"twenty":-11.41285,"median":-9.666597,"eighty":-8.919616,"marketCap":5995933200},{"date":"2024-09-20","current":-13.175636,"twenty":-11.495182,"median":-9.727036,"eighty":-8.943786,"marketCap":6129176160},{"date":"2024-09-27","current":-11.412309,"twenty":-11.503472,"median":-9.834343,"eighty":-8.968754,"marketCap":5340821980},{"date":"2024-10-04","current":-10.630177,"twenty":-11.500266,"median":-9.955419,"eighty":-8.992959,"marketCap":4952196680},{"date":"2024-10-10","current":-9.640046,"twenty":-11.496891,"median":-9.984689,"eighty":-9.012278,"marketCap":4463639160},{"date":"2024-10-18","current":-7.823087,"twenty":-11.483911,"median":-9.882424,"eighty":-8.891475,"marketCap":3602001352},{"date":"2024-10-25","current":-6.637022,"twenty":-11.464072,"median":-9.731881,"eighty":-8.768492,"marketCap":3055705216},{"date":"2024-11-01","current":-6.266219,"twenty":-11.439791,"median":-9.666597,"eighty":-8.552796,"marketCap":2886930800},{"date":"2024-11-08","current":-6.11978,"twenty":-11.412634,"median":-9.628889,"eighty":-8.354641,"marketCap":2798102160},{"date":"2024-11-15","current":-4.903744,"twenty":-11.406399,"median":-9.610023,"eighty":-8.146037,"marketCap":2225157432},{"date":"2024-11-22","current":-4.446271,"twenty":-11.39192,"median":-9.574881,"eighty":-7.917147,"marketCap":2016410128},{"date":"2024-11-29","current":-5.262129,"twenty":-11.380385,"median":-9.536435,"eighty":-7.700796,"marketCap":2385048984},{"date":"2024-12-06","current":-5.795133,"twenty":-11.346153,"median":-9.513744,"eighty":-7.24659,"marketCap":2620444880},{"date":"2024-12-13","current":-4.23234,"twenty":-11.292835,"median":-9.462151,"eighty":-6.614509,"marketCap":1912036476},{"date":"2024-12-20","current":-3.65763,"twenty":-11.272236,"median":-9.353096,"eighty":-6.423955,"marketCap":1643329840},{"date":"2024-12-27","current":-3.704989,"twenty":-11.261539,"median":-9.289241,"eighty":-6.377951,"marketCap":1663316284},{"date":"2025-01-03","current":-3.459219,"twenty":-11.261057,"median":-9.234052,"eighty":-6.353973,"marketCap":1554501200},{"date":"2025-01-10","current":-3.422771,"twenty":-11.250301,"median":-9.146052,"eighty":-6.232964,"marketCap":1532294040},{"date":"2025-01-17","current":-3.325837,"twenty":-11.24332,"median":-9.119354,"eighty":-5.607796,"marketCap":1490100436},{"date":"2025-01-24","current":-3.940539,"twenty":-11.188065,"median":-9.092192,"eighty":-5.378133,"marketCap":1776572800},{"date":"2025-01-28","current":-4.706176,"twenty":-11.17068,"median":-9.087355,"eighty":-5.266211,"marketCap":2131887360},{"date":"2025-02-07","current":-3.301677,"twenty":-11.154739,"median":-9.066381,"eighty":-4.958001,"marketCap":1487879720},{"date":"2025-02-14","current":-3.418254,"twenty":-11.143754,"median":-8.989713,"eighty":-4.539173,"marketCap":1536735472},{"date":"2025-02-21","current":-3.43891,"twenty":-11.106485,"median":-8.919616,"eighty":-4.354459,"marketCap":1554501200},{"date":"2025-02-28","current":-3.351703,"twenty":-11.093486,"median":-8.819713,"eighty":-4.122814,"marketCap":1510086880},{"date":"2025-03-07","current":-3.387392,"twenty":-11.071174,"median":-8.759388,"eighty":-3.975573,"marketCap":1532294040},{"date":"2025-03-14","current":-5.398225,"twenty":-11.023325,"median":-8.622598,"eighty":-3.975573,"marketCap":2442787600},{"date":"2025-03-21","current":-4.408646,"twenty":-11.005989,"median":-8.475358,"eighty":-3.996365,"marketCap":1994202968},{"date":"2025-03-28","current":-4.427424,"twenty":-10.958538,"median":-8.354936,"eighty":-4.069456,"marketCap":1998644400},{"date":"2025-04-03","current":-5.532239,"twenty":-10.950727,"median":-8.251895,"eighty":-4.071454,"marketCap":1987540820},{"date":"2025-04-11","current":-5.176788,"twenty":-10.949179,"median":-8.134698,"eighty":-4.113712,"marketCap":1843194280},{"date":"2025-04-17","current":-5.605956,"twenty":-10.931954,"median":-8.013266,"eighty":-4.15012,"marketCap":1998644400},{"date":"2025-04-25","current":-6.813611,"twenty":-10.860673,"median":-7.855635,"eighty":-4.203093,"marketCap":2433904736},{"date":"2025-05-02","current":-6.97286,"twenty":-10.741685,"median":-7.823087,"eighty":-4.240312,"marketCap":2496084784},{"date":"2025-05-09","current":-6.850326,"twenty":-10.62989,"median":-7.688151,"eighty":-4.256936,"marketCap":2469436192},{"date":"2025-05-16","current":-6.660384,"twenty":-10.625613,"median":-7.362552,"eighty":-4.28571,"marketCap":2420580440},{"date":"2025-05-23","current":-6.920763,"twenty":-10.596701,"median":-7.188701,"eighty":-4.327055,"marketCap":2522733376},{"date":"2025-05-30","current":-6.975387,"twenty":-10.531077,"median":-7.035719,"eighty":-4.335168,"marketCap":2553823400},{"date":"2025-06-06","current":-8.954176,"twenty":-10.530643,"median":-7.056435,"eighty":-4.354459,"marketCap":3286659680},{"date":"2025-06-13","current":-10.1118,"twenty":-10.525842,"median":-7.245424,"eighty":-4.362058,"marketCap":3713037152},{"date":"2025-06-20","current":-9.295434,"twenty":-10.49786,"median":-7.449742,"eighty":-4.377592,"marketCap":3406578344},{"date":"2025-06-27","current":-9.088195,"twenty":-10.44408,"median":-7.654473,"eighty":-4.399074,"marketCap":3339956864},{"date":"2025-07-04","current":-9.256954,"twenty":-10.441448,"median":-7.771425,"eighty":-4.408646,"marketCap":3402136912},{"date":"2025-07-11","current":-9.278386,"twenty":-10.438605,"median":-7.855635,"eighty":-4.408983,"marketCap":3406578344},{"date":"2025-07-18","current":-10.375245,"twenty":-10.375245,"median":-8.023578,"eighty":-4.415927,"marketCap":3806307224},{"date":"2025-07-25","current":-11.242346,"twenty":-10.444738,"median":-8.163045,"eighty":-4.427424,"marketCap":4139414624},{"date":"2025-08-01","current":-12.956889,"twenty":-10.531115,"median":-8.317696,"eighty":-4.446271,"marketCap":4741228660},{"date":"2025-08-08","current":-12.531071,"twenty":-10.816023,"median":-8.356409,"eighty":-4.497422,"marketCap":4596882120},{"date":"2025-08-15","current":-13.616918,"twenty":-10.950727,"median":-8.486422,"eighty":-4.706176,"marketCap":4987728136},{"date":"2025-08-22","current":-28.922954,"twenty":-11.024815,"median":-8.611071,"eighty":-4.860396,"marketCap":6035906088},{"date":"2025-08-29","current":-26.076607,"twenty":-11.152426,"median":-8.643647,"eighty":-4.89511,"marketCap":5467884128},{"date":"2025-09-05","current":-27.424941,"twenty":-11.24224,"median":-8.759388,"eighty":-4.895913,"marketCap":5744911480},{"date":"2025-09-12","current":-33.976118,"twenty":-11.261539,"median":-8.783884,"eighty":-4.903744,"marketCap":7130048240},{"date":"2025-09-19","current":-32.137812,"twenty":-11.3835,"median":-8.872714,"eighty":-4.920955,"marketCap":6739485088},{"date":"2025-09-26","current":-31.917438,"twenty":-11.446602,"median":-8.942813,"eighty":-4.93749,"marketCap":6675905040},{"date":"2025-10-03","current":-36.693474,"twenty":-11.494681,"median":-8.957754,"eighty":-4.939756,"marketCap":7693185808},{"date":"2025-10-10","current":-31.866218,"twenty":-11.50418,"median":-8.989713,"eighty":-4.971797,"marketCap":6671363608},{"date":"2025-10-17","current":-31.02267,"twenty":-11.536491,"median":-9.052042,"eighty":-5.060821,"marketCap":6489706328},{"date":"2025-10-24","current":-25.824743,"twenty":-11.67702,"median":-9.080681,"eighty":-5.119056,"marketCap":5404304080},{"date":"2025-10-31","current":-23.597698,"twenty":-11.854109,"median":-9.087898,"eighty":-5.129572,"marketCap":4945619448},{"date":"2025-11-07","current":-20.869587,"twenty":-12.197299,"median":-9.096784,"eighty":-5.138538,"marketCap":4371128300},{"date":"2025-11-13","current":-21.952253,"twenty":-12.407907,"median":-9.107782,"eighty":-5.151718,"marketCap":4610921056}],"updateTime":1763110065281},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02509\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1113909324","title":"Qyuns Therapeutics (Stock Code: 2509) and Roche Ink Global Exclusive License for QX031N","url":"https://stock-news.laohu8.com/highlight/detail?id=1113909324","media":"Bulletin Express","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113909324?lang=en_us&edition=fundamental","pubTime":"2025-10-28 18:43","pubTimestamp":1761648209,"startTime":"0","endTime":"0","summary":"Qyuns Therapeutics Co., Ltd. (Stock Code: 2509) entered into a global exclusive collaboration and license agreement with F. Hoffmann-La Roche Ltd (Roche) on October 28, 2025. Under the agreement,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509"],"gpt_icon":0},{"id":"1119095115","title":"Qyuns Therapeutics (2509) Announces Positive Phase III Results for Crusekitug in Ankylosing Spondylitis","url":"https://stock-news.laohu8.com/highlight/detail?id=1119095115","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119095115?lang=en_us&edition=fundamental","pubTime":"2025-10-28 18:43","pubTimestamp":1761648188,"startTime":"0","endTime":"0","summary":"Qyuns Therapeutics Co., Ltd. (2509) announced that on October 27, 2025, its independently developed monoclonal antibody Crusekitug (QX002N) for ankylosing spondylitis was highlighted in an oral...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509"],"gpt_icon":0},{"id":"1147265146","title":"QYUNS-B (02509) Enters Global Exclusive Licensing Agreement with Roche for QX031N","url":"https://stock-news.laohu8.com/highlight/detail?id=1147265146","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147265146?lang=en_us&edition=fundamental","pubTime":"2025-10-28 18:10","pubTimestamp":1761646241,"startTime":"0","endTime":"0","summary":"QYUNS-B (02509) announced on October 28, 2025, that the company has entered into a global exclusive collaboration and licensing agreement with F. Hoffmann-La Roche Ltd (Roche). Under the agreement,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02509"],"gpt_icon":0},{"id":"1170133925","title":"QYUNS-B (02509): QX002N (Lusekizumab) Phase III Clinical Trial Results for Ankylosing Spondylitis Presented at 2025 ACR Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=1170133925","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170133925?lang=en_us&edition=fundamental","pubTime":"2025-10-28 17:56","pubTimestamp":1761645383,"startTime":"0","endTime":"0","summary":"QYUNS-B (02509) announced that on October 27, 2025, the Phase III clinical trial results of its self-developed drug, QX002N (Lusekizumab), for the treatment of ankylosing spondylitis (AS) were...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACR","III","BK4110","BK1161","02509","BK4134"],"gpt_icon":0},{"id":"2578621931","title":"Qyuns Therapeutics Grants Roche Global Exclusive License for QX031N","url":"https://stock-news.laohu8.com/highlight/detail?id=2578621931","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578621931?lang=en_us&edition=fundamental","pubTime":"2025-10-28 17:56","pubTimestamp":1761645364,"startTime":"0","endTime":"0","summary":"Qyuns Therapeutics Co. Ltd. announced that it has entered into a global exclusive collaboration and license agreement with F. Hoffmann-La Roche Ltd  for its investigational product QX031N. Under the terms of the agreement, Qyuns Therapeutics will grant Roche the exclusive global rights to develop, manufacture, and commercialize QX031N. The company will receive a one-time, non-refundable upfront payment of US$75 million and is eligible to receive up to US$995 million in milestone payments related to development, regulatory approval, and commercialization of the product, as well as tiered royalties on potential future sales. QX031N is a long-acting bispecific antibody intended for the treatment of respiratory diseases such as COPD and asthma. The agreement is subject to customary closing conditions, including regulatory approvals.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely info","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251028:nNDL36m36x:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02509"],"gpt_icon":0},{"id":"2578931678","title":"Qyuns Therapeutics Reports Positive Phase III Results for Crusekitug in Ankylosing Spondylitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2578931678","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578931678?lang=en_us&edition=fundamental","pubTime":"2025-10-28 17:56","pubTimestamp":1761645361,"startTime":"0","endTime":"0","summary":"Qyuns Therapeutics Co., Ltd. announced that the Phase III clinical trial results for Crusekitug , a drug developed for the treatment of ankylosing spondylitis, were presented at the 2025 annual meeting of the American College of Rheumatology  in Chicago. The multicenter, randomized, double-blind, placebo-controlled study involved 641 patients across 58 research centers in China. The trial demonstrated that at week 16, the ASAS40 response rate in the Crusekitug group was 40.4%, compared to 18.9% in the placebo group, with statistical significance . The ASAS20 response rate for Crusekitug was 65.2%, also significantly higher than the placebo group. The study included a 48-week treatment period and a 4-week safety follow-up.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251028:nNDL63hc04:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02509"],"gpt_icon":0},{"id":"2578931537","title":"Qyuns Therapeutics - Grants Roche Global Exclusive Right to Develop, Others QX031n","url":"https://stock-news.laohu8.com/highlight/detail?id=2578931537","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578931537?lang=en_us&edition=fundamental","pubTime":"2025-10-28 17:51","pubTimestamp":1761645114,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251028:nFWN3W90FF:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02509","BK1161"],"gpt_icon":0},{"id":"2578931531","title":"Qyuns Therapeutics - to Receive $75 Mln Upfront and up to $995 Mln in Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2578931531","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578931531?lang=en_us&edition=fundamental","pubTime":"2025-10-28 17:51","pubTimestamp":1761645114,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251028:nFWN3W90FF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02509","BK1161"],"gpt_icon":0},{"id":"2578393153","title":"Qyuns Therapeutics - Announces Exclusive License Agreement With F. Hoffmann-La Roche","url":"https://stock-news.laohu8.com/highlight/detail?id=2578393153","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578393153?lang=en_us&edition=fundamental","pubTime":"2025-10-28 17:51","pubTimestamp":1761645114,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251028:nFWN3W90FF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02509"],"gpt_icon":0},{"id":"1100196411","title":"HK Movers | Biomedical Stocks Surge With TransThera Sciences up 42%","url":"https://stock-news.laohu8.com/highlight/detail?id=1100196411","media":"Tiger Newspress","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100196411?lang=en_us&edition=fundamental","pubTime":"2025-10-16 10:54","pubTimestamp":1760583262,"startTime":"0","endTime":"0","summary":"Biomedical stocks surged in Hong Kong. TransThera Sciences rose 42%; 3SBio, Qyuns Therapeutics, and Henlius Biotech rose 9%; Duality Biotherapeutics rose 5%; WuXi Biologics rose 3%; WuXi AppTec rose 2%.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"fc7ccc68210fffcf55d2ffc6613e5571","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530","02696","09606","02617","02359","02269","02509"],"gpt_icon":0},{"id":"2575642167","title":"Qyuns Therapeutics Unit Passes EU Qualified Person Audit; Shares Down 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2575642167","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575642167?lang=en_us&edition=fundamental","pubTime":"2025-10-13 13:35","pubTimestamp":1760333702,"startTime":"0","endTime":"0","summary":"Qyuns Therapeutics  said its unit Jiangsu Cellularforce Biopharma has successfully passed the EU Qualified Person audit, confirming that its industrialization base meets European Union Good Manufacturing Practice standards, according to an Oct. 10 Hong Kong bourse filing.Shares of the firm were down over 8% in Monday afternoon trade.The audit, conducted over three days by a senior EU QP under EudraLex Volume 4 guidelines, recognized the unit's high-quality management system, advanced facilities, and technical capabilities.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","02509","BK1161","BK4539","LENZ","BK4139","BK4156"],"gpt_icon":0},{"id":"1122486676","title":"QYUNS-B (02509): Subsidiary Successfully Passes EU Qualified Person Audit for Manufacturing Base","url":"https://stock-news.laohu8.com/highlight/detail?id=1122486676","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122486676?lang=en_us&edition=fundamental","pubTime":"2025-10-10 18:28","pubTimestamp":1760092097,"startTime":"0","endTime":"0","summary":"QYUNS-B (02509) announced that its subsidiary, Jiangsu Saifusi Biotechnology Co., Ltd. (\"Saifusi\"), has successfully passed the European Union Qualified Person (QP) audit and officially received a...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FESXmain","FSXEmain","BK1161","02509"],"gpt_icon":0},{"id":"2574122909","title":"Qyuns Therapeutics Industrialization Base Passes EU QP Audit Meeting EU GMP Standards","url":"https://stock-news.laohu8.com/highlight/detail?id=2574122909","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574122909?lang=en_us&edition=fundamental","pubTime":"2025-10-10 18:19","pubTimestamp":1760091566,"startTime":"0","endTime":"0","summary":"Qyuns Therapeutics Co. Ltd. has announced that its subsidiary, Jiangsu Cellularforce Biopharma Co., Ltd., has successfully passed the EU Qualified Person  audit and received the official compliance audit report. This achievement confirms that the company's industrialization base meets EU Good Manufacturing Practice  standards for pharmaceuticals. The audit, conducted by a senior QP in accordance with EudraLex Volume 4 and related guidelines, recognized Cellularforce's high-standard quality management system, advanced facilities, and professional capabilities. This milestone supports the company's efforts in providing globally compliant biologics CDMO services. No grant or funding involving multiple organizations was mentioned in the announcement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251010:nNDL8TWJGC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509","BK1161"],"gpt_icon":0},{"id":"2572868850","title":"Qyuns Therapeutics (SEHK:2509): Evaluating Valuation After Recent Stock Surge","url":"https://stock-news.laohu8.com/highlight/detail?id=2572868850","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572868850?lang=en_us&edition=fundamental","pubTime":"2025-10-03 16:27","pubTimestamp":1759480046,"startTime":"0","endTime":"0","summary":"Qyuns Therapeutics (SEHK:2509) has caught some attention lately as its stock price climbed over 1% in a day and surged nearly 21% in the past week. Investors are watching these moves closely, considering what they could signal for the company’s current valuation.\nSee our latest analysis for Qyuns Therapeutics.\nThe recent upswing in Qyuns Therapeutics’ share price comes after a string of modest but persistent gains over the past year. While the 1-year total shareholder return is just 0.5%, the...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2509/qyuns-therapeutics-shares/news/qyuns-therapeutics-sehk2509-evaluating-valuation-after-recen","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2509/qyuns-therapeutics-shares/news/qyuns-therapeutics-sehk2509-evaluating-valuation-after-recen","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LENZ","BK4007","BK1161","BK4539","BK4139","02509"],"gpt_icon":0},{"id":"1125679907","title":"Tianfeng Securities Initiates Coverage on QYUNS-B (02509) with \"Buy\" Rating, Target Price HK$40.25","url":"https://stock-news.laohu8.com/highlight/detail?id=1125679907","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125679907?lang=en_us&edition=fundamental","pubTime":"2025-09-30 11:02","pubTimestamp":1759201354,"startTime":"0","endTime":"0","summary":"Tianfeng Securities has initiated coverage on QYUNS-B (02509) with a \"Buy\" rating, projecting the company's revenue for 2025-2027 at RMB 3.22/4.41/5.93 billion respectively. The firm assigns a 26x PS...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK0276","02509","601162"],"gpt_icon":0},{"id":"1141949628","title":"Hong Kong Pharmaceuticals Rise as Trump Drug Tariffs Show Limited Impact; Q4 BD Events Expected","url":"https://stock-news.laohu8.com/highlight/detail?id=1141949628","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141949628?lang=en_us&edition=fundamental","pubTime":"2025-09-29 14:48","pubTimestamp":1759128513,"startTime":"0","endTime":"0","summary":"Most pharmaceutical stocks gained strength in Hong Kong trading. As of press time, IMMUNEONCO-B (01541) surged 18.98% to HK$13.48; QYUNS-B (02509) climbed 12.11% to HK$32.96; XTALPI (02228) advanced...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"3452d085f48a0e569f128ec4585d109f","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01167","BK1617","159938","HSCEI","02509","BK1583","07226","LU1969619763.USD","BK1515","BK1161","09939","BK1141","LU2328871848.SGD","01541","02228","BK1574","BK4614","09995","YANG"],"gpt_icon":0},{"id":"1107739457","title":"Hong Kong Stock Alert | QYUNS-B (02509) Surges Over 10% Again as Mature Pipeline Enters Monetization Phase, Seleixin Market Sales Accelerating","url":"https://stock-news.laohu8.com/highlight/detail?id=1107739457","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107739457?lang=en_us&edition=fundamental","pubTime":"2025-09-08 10:28","pubTimestamp":1757298504,"startTime":"0","endTime":"0","summary":"QYUNS-B (02509) surged over 10% again, rising 9.64% to HK$27.74 as of press time, with trading volume reaching HK$18.69 million. On the news front, QYUNS-B previously announced its first half 2025...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4166","LU1235295612.USD","LU1046422090.SGD","BK1161","BK4579","LX","BK4531","02509","LU0049112450.USD"],"gpt_icon":0},{"id":"1140944703","title":"Hong Kong Stock Alert | QYUNS-B (02509) Surges Over 7% Intraday as Company Accelerates Pipeline Market Potential Realization with Bispecific Antibody Programs Targeting International Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=1140944703","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1140944703?lang=en_us&edition=fundamental","pubTime":"2025-09-05 11:32","pubTimestamp":1757043164,"startTime":"0","endTime":"0","summary":"QYUNS-B (02509) surged over 7% during trading, and as of press time, the stock was up 6.13% to HK$24.94 with a turnover of HK$12.21 million. On the news front, QYUNS-B's interim results showed that...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509","BK1161"],"gpt_icon":0},{"id":"2562078551","title":"Qyuns Therapeutics Raises HK$100 Million via Share Placement; Shares Rise 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562078551","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562078551?lang=en_us&edition=fundamental","pubTime":"2025-08-26 16:17","pubTimestamp":1756196229,"startTime":"0","endTime":"0","summary":"Qyuns Therapeutics  said it has completed a HK$100 million share placement to TruMed Health Innovation Fund, according to a Monday Hong Kong bourse filing.Shares of the biopharmaceutical firm gained over 3% in afternoon trading on Tuesday.It issued 5 million new H-shares at HK$20 each, representing about 2.2% of its enlarged share capital.Proceeds will be used mainly to repay debt, with a portion earmarked for advancing its drug pipeline, Qyuns said.The company confirmed its public float remains above 25% after the issuance.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","02509","BK4007","BK4539","LENZ","BK1161"],"gpt_icon":0},{"id":"1153314071","title":"QYUNS-B (02509) Completes Placement of 5 Million Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1153314071","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153314071?lang=en_us&edition=fundamental","pubTime":"2025-08-25 21:36","pubTimestamp":1756128986,"startTime":"0","endTime":"0","summary":"QYUNS-B (02509) announced that all conditions under the placement agreement have been fulfilled, and the placement was completed in accordance with the terms of the placement agreement on August 25,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02509"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":56,"code":"91000000","status":"200"}]}}